Product details
Background:Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.
• Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19., PMID:34530915
• CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells., PMID:25840792
• Retinopathy severity correlates with RANTES concentrations and CCR 5-positive microvesicles in diabetes., PMID:31891363
• Effects of conventional CPB and mini-CPB on neutrophils CD162, CD166 and CD195 expression., PMID:27625334
• Acute response of peripheral CCr5 chemoreceptor and NK cells in individuals submitted to a single session of low-intensity strength exercise with blood flow restriction., PMID:25643617
• Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy., PMID:27781132






